Alteplase for treating acute ischaemic stroke
KEYWORDS: alteplase, stroke, manufacturer, treatment, committee, patients, hour, acute, ischaemic, window, hours, model, ischaemic stroke, acute ischaemic, death

resources. The Committee also agreed with the clinical specialists that extending the time window for treatment should not diminish the urgency with which people suspected of having an acute ischaemic stroke should be treated. 4.11 The Committee discussed whether any equality issues required consideration in this appraisal. The Committee was aware that extension of the licence to 4.5 hours after symptom onset may enable increased access to treatment with alteplase for patients in remote or rural locations. Alteplase for treating acute ischaemic stroke (TA264) 5 Implementation 5.1 Section 7 of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires integrated care boards, NHS England and, with respect to their public health functions, local authorities to comply with the recommendations in this evaluation within 3 months of its date of publication. 5.2 The Welsh ministers have issued directions to the NHS in Wales on implementing NICE technology appraisal guidance. When a NICE technology appraisal guidance recommends the use of a drug or treatment, or other technology, the NHS in Wales must usually provide funding and resources for it within 2 months of the first publication of the
